Inactive Instrument
Cerevel Therapeutics Holdings, Inc. Stock
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
| 1 day | +0.74% |
| 3 years | 21.86 |  | 44.99 |
| 5 years | 19.59 | | 46.16 |
| 10 years | 9 | | 46.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Renger
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/05/2019 |
Matthew Calistri
IRC | Investor Relations Contact | - | - |
Paul Burgess
PRN | Corporate Officer/Principal | 53 | 20/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Baron
BRD | Director/Board Member | 57 | 20/01/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 1/8/24 | Issuer sale | Chief Medical Officer | 1,495,399 | 0.8208% | ||
| 1/8/24 | Issuer sale | Director | 108,985 | 0.0598% | ||
| 1/8/24 | Issuer sale | Director | 137,525 | 0.0755% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -.--% | - | - | 8.19B | |
| -2.37% | -5.03% | +39.49% | +62.39% | 62.23B | |
| +1.07% | +1.23% | +11.64% | +70.19% | 54.92B | |
| +0.34% | +2.61% | +20.99% | +98.24% | 55.26B | |
| +0.44% | -5.02% | +20.59% | +30.79% | 42.59B | |
| -1.83% | -3.41% | +13.37% | +92.39% | 41.08B | |
| +3.03% | +4.61% | +228.33% | +779.06% | 40.33B | |
| +0.47% | +25.26% | +101.34% | +85.84% | 33.12B | |
| +0.21% | +1.05% | +14.81% | +46.96% | 32.61B | |
| -1.51% | +14.05% | -41.85% | +335.81% | 23.98B | |
| Average | +0.04% | +4.27% | +45.41% | +177.96% | 42.9B | |
| Weighted average by Cap. | -0.05% | +2.74% | +45.91% | +160.89% |
Employees
355
